South Korea · Delayed Price · Currency is KRW BIOBIJOU Statistics
Total Valuation
BIOBIJOU has a market cap or net worth of KRW 223.36 billion. The enterprise value is 208.31 billion.
| Market Cap | 223.36B |
| Enterprise Value | 208.31B |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | Dec 29, 2026 |
Share Statistics
BIOBIJOU has 14.75 million shares outstanding. The number of shares has increased by 22.81% in one year.
| Current Share Class | 14.75M |
| Shares Outstanding | 14.75M |
| Shares Change (YoY) | +22.81% |
| Shares Change (QoQ) | -1.00% |
| Owned by Insiders (%) | 10.57% |
| Owned by Institutions (%) | 5.09% |
| Float | 4.55M |
Valuation Ratios
The trailing PE ratio is 35.33.
| PE Ratio | 35.33 |
| Forward PE | n/a |
| PS Ratio | 7.82 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | 3,266.78 |
| P/OCF Ratio | 580.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.02, with an EV/FCF ratio of 3,046.62.
| EV / Earnings | 31.95 |
| EV / Sales | 7.29 |
| EV / EBITDA | 36.02 |
| EV / EBIT | 41.63 |
| EV / FCF | 3,046.62 |
Financial Position
The company has a current ratio of 15.44, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.44 |
| Quick Ratio | 9.47 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 5.57 |
| Interest Coverage | 272.86 |
Financial Efficiency
Return on equity (ROE) is 10.41% and return on invested capital (ROIC) is 9.41%.
| Return on Equity (ROE) | 10.41% |
| Return on Assets (ROA) | 4.72% |
| Return on Invested Capital (ROIC) | 9.41% |
| Return on Capital Employed (ROCE) | 7.81% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 679.95M |
| Profits Per Employee | 155.22M |
| Employee Count | 42 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.77 |
Taxes
In the past 12 months, BIOBIJOU has paid 1.62 billion in taxes.
| Income Tax | 1.62B |
| Effective Tax Rate | 19.91% |
Stock Price Statistics
The stock price has increased by +25.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +25.12% |
| 50-Day Moving Average | 12,258.80 |
| 200-Day Moving Average | 9,783.05 |
| Relative Strength Index (RSI) | 77.12 |
| Average Volume (20 Days) | 117,513 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIOBIJOU had revenue of KRW 28.56 billion and earned 6.52 billion in profits. Earnings per share was 428.59.
| Revenue | 28.56B |
| Gross Profit | 15.97B |
| Operating Income | 5.00B |
| Pretax Income | 8.13B |
| Net Income | 6.52B |
| EBITDA | 5.78B |
| EBIT | 5.00B |
| Earnings Per Share (EPS) | 428.59 |
Balance Sheet
The company has 15.45 billion in cash and 380.69 million in debt, with a net cash position of 15.07 billion or 1,021.31 per share.
| Cash & Cash Equivalents | 15.45B |
| Total Debt | 380.69M |
| Net Cash | 15.07B |
| Net Cash Per Share | 1,021.31 |
| Equity (Book Value) | 63.95B |
| Book Value Per Share | 4,333.55 |
| Working Capital | 48.68B |
Cash Flow
In the last 12 months, operating cash flow was 384.83 million and capital expenditures -316.45 million, giving a free cash flow of 68.37 million.
| Operating Cash Flow | 384.83M |
| Capital Expenditures | -316.45M |
| Depreciation & Amortization | 779.43M |
| Net Borrowing | -303.79M |
| Free Cash Flow | 68.37M |
| FCF Per Share | 4.63 |
Margins
Gross margin is 55.91%, with operating and profit margins of 17.52% and 22.83%.
| Gross Margin | 55.91% |
| Operating Margin | 17.52% |
| Pretax Margin | 28.47% |
| Profit Margin | 22.83% |
| EBITDA Margin | 20.25% |
| EBIT Margin | 17.52% |
| FCF Margin | 0.24% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.66%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 0.66% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.08% |
| FCF Payout Ratio | 2,157.72% |
| Buyback Yield | -22.81% |
| Shareholder Yield | -22.14% |
| Earnings Yield | 2.83% |
| FCF Yield | 0.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOBIJOU has an Altman Z-Score of 34.33 and a Piotroski F-Score of 5.
| Altman Z-Score | 34.33 |
| Piotroski F-Score | 5 |